Morris Brown, MD
Queen Mary University of London, UK
Dr. Brown is Professor of Endocrine Hypertension at the Centre for Clinical Pharmacology and Precision Medicine at Queen Mary University of London. He qualified in classics and medicine from Camebridge and trained in clinical pharmacology.
Dr. Browns research aims to discover causes of hypertension and to optimise its management. As President of the British Hypertension Society 2005-2007 he established a research network that conducted a series of clinical trials, the ‘PATHWAY’ programme establishing optimal treatment for different categories of Hypertension. His current research is mainly focussed on the adrenal gland, and the small aldosterone-producing adenomas which are a common cause of hypertension, spanning from genetics and molecular biology to invasive and non-invasive techniques for diagnosis.
Timothy A. McKinsey, PhD
University of Colorado Anschutz Medical Campus, Denver, USA
Dr. McKinsey is a Professor in the Department of Medicine at the University of Colorado Anschutz Medical Campus in Denver, where he holds the Joseph and Rose LaConte Endowed Chair in Cardiology. Dr. McKinsey is also Associate Division Head for Translational Research and Founding Director of the university’s Consortium for Fibrosis Research & Translation (CFReT; www.cfret.org). He obtained a PhD in Microbiology and Immunology from Vanderbilt University School of Medicine, studying NF-kB signaling in the laboratory of Dr. Dean Ballard. Dr. McKinsey’s postdoctoral training was done in the laboratory of Dr. Eric Olson at the University of Texas Southwestern Medical Center in Dallas, where he investigated transcriptional control of muscle development and growth. Prior to joining the faculty of the University of Colorado, Dr. McKinsey spent eight years in industry (Myogen/Gilead), where he recruited and managed a team of 18 scientists focused on small molecule drug discovery for cardiovascular/pulmonary/renal diseases. Current interests of Dr. McKinsey’s lab include defining signaling and epigenetic mechanisms that control heart failure.